The failure of immunomodulation therapy in heart failure: does the statins "paradigm" prove the rule?

Inflammation is an important process and an underlying mechanism involved in atherogenesis as well as the clinical manifestations following coronary artery disease (CAD). Evidence suggests that chronic heart failure (CHF) is associated with an increased inflammatory process. Pro-inflammatory cytokin...

Full description

Bibliographic Details
Main Authors: Tousoulis, D, Papageorgiou, N, Briasoulis, A, Antoniades, C, Stefanadis, C
Format: Journal article
Language:English
Published: 2010
_version_ 1797102575649030144
author Tousoulis, D
Papageorgiou, N
Briasoulis, A
Antoniades, C
Stefanadis, C
author_facet Tousoulis, D
Papageorgiou, N
Briasoulis, A
Antoniades, C
Stefanadis, C
author_sort Tousoulis, D
collection OXFORD
description Inflammation is an important process and an underlying mechanism involved in atherogenesis as well as the clinical manifestations following coronary artery disease (CAD). Evidence suggests that chronic heart failure (CHF) is associated with an increased inflammatory process. Pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-a), interleukin-6 (IL-6), interleukin-1 (IL-1) and adhesion molecules are elevated in states of CHF and are related to long term prognosis. Statins are among the most effective compounds reducing morbidity and mortality in patients with, or at increased risk of, CAD. Efficacy and safety of statin treatment has not been validated in patients with CHF. Several studies have reported that statins could be beneficial in patients with CHF. In addition, the beneficial effects of statins have been largely attributed to their anti-inflammatory properties. However, recent randomized, double-blind, placebo-controlled trials reported that statins did not affect clinical outcomes in patients with CHF of any cause. These data support the notion that current immunomodulation approaches in heart failure are not successful. Thus, more large scale clinical trials are required to evaluate the impact of statins on immune imbalance and its restoration in patients with CHF.
first_indexed 2024-03-07T06:07:52Z
format Journal article
id oxford-uuid:ee742557-951f-4248-99fc-8ee490c2aa1f
institution University of Oxford
language English
last_indexed 2024-03-07T06:07:52Z
publishDate 2010
record_format dspace
spelling oxford-uuid:ee742557-951f-4248-99fc-8ee490c2aa1f2022-03-27T11:32:53ZThe failure of immunomodulation therapy in heart failure: does the statins "paradigm" prove the rule?Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ee742557-951f-4248-99fc-8ee490c2aa1fEnglishSymplectic Elements at Oxford2010Tousoulis, DPapageorgiou, NBriasoulis, AAntoniades, CStefanadis, CInflammation is an important process and an underlying mechanism involved in atherogenesis as well as the clinical manifestations following coronary artery disease (CAD). Evidence suggests that chronic heart failure (CHF) is associated with an increased inflammatory process. Pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-a), interleukin-6 (IL-6), interleukin-1 (IL-1) and adhesion molecules are elevated in states of CHF and are related to long term prognosis. Statins are among the most effective compounds reducing morbidity and mortality in patients with, or at increased risk of, CAD. Efficacy and safety of statin treatment has not been validated in patients with CHF. Several studies have reported that statins could be beneficial in patients with CHF. In addition, the beneficial effects of statins have been largely attributed to their anti-inflammatory properties. However, recent randomized, double-blind, placebo-controlled trials reported that statins did not affect clinical outcomes in patients with CHF of any cause. These data support the notion that current immunomodulation approaches in heart failure are not successful. Thus, more large scale clinical trials are required to evaluate the impact of statins on immune imbalance and its restoration in patients with CHF.
spellingShingle Tousoulis, D
Papageorgiou, N
Briasoulis, A
Antoniades, C
Stefanadis, C
The failure of immunomodulation therapy in heart failure: does the statins "paradigm" prove the rule?
title The failure of immunomodulation therapy in heart failure: does the statins "paradigm" prove the rule?
title_full The failure of immunomodulation therapy in heart failure: does the statins "paradigm" prove the rule?
title_fullStr The failure of immunomodulation therapy in heart failure: does the statins "paradigm" prove the rule?
title_full_unstemmed The failure of immunomodulation therapy in heart failure: does the statins "paradigm" prove the rule?
title_short The failure of immunomodulation therapy in heart failure: does the statins "paradigm" prove the rule?
title_sort failure of immunomodulation therapy in heart failure does the statins paradigm prove the rule
work_keys_str_mv AT tousoulisd thefailureofimmunomodulationtherapyinheartfailuredoesthestatinsparadigmprovetherule
AT papageorgioun thefailureofimmunomodulationtherapyinheartfailuredoesthestatinsparadigmprovetherule
AT briasoulisa thefailureofimmunomodulationtherapyinheartfailuredoesthestatinsparadigmprovetherule
AT antoniadesc thefailureofimmunomodulationtherapyinheartfailuredoesthestatinsparadigmprovetherule
AT stefanadisc thefailureofimmunomodulationtherapyinheartfailuredoesthestatinsparadigmprovetherule
AT tousoulisd failureofimmunomodulationtherapyinheartfailuredoesthestatinsparadigmprovetherule
AT papageorgioun failureofimmunomodulationtherapyinheartfailuredoesthestatinsparadigmprovetherule
AT briasoulisa failureofimmunomodulationtherapyinheartfailuredoesthestatinsparadigmprovetherule
AT antoniadesc failureofimmunomodulationtherapyinheartfailuredoesthestatinsparadigmprovetherule
AT stefanadisc failureofimmunomodulationtherapyinheartfailuredoesthestatinsparadigmprovetherule